MedKoo Cat#: 206094 | Name: Dusquetide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dusquetide, also known as SGX-942 and SGX94, is synthetic, 5-amino acid peptide and innate defense regulator (IDR), with immunomodulating, anti-inflammatory, anti-infective and anti-mucositis activities. Upon intravenous administration, SGX942 binds to the ZZ domain of sequestosome-1, also called p62, and activates regulatory signaling transduction pathways involved in the modulation of the innate immune system, such as those mediated by mitogen-activated protein kinase (MAPK) p38 and CCAAT-enhancer-binding protein.

Chemical Structure

Dusquetide
Dusquetide
CAS#931395-42-5

Theoretical Analysis

MedKoo Cat#: 206094

Name: Dusquetide

CAS#: 931395-42-5

Chemical Formula: C25H47N9O5

Exact Mass: 553.3700

Molecular Weight: 553.71

Elemental Analysis: C, 54.23; H, 8.56; N, 22.77; O, 14.45

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SGX942; SGX942; SGX 942. SGX94; SGX-94; SGX 94; dusquetide; L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alaninamide.
IUPAC/Chemical Name
(S)-1-(L-arginyl-L-isoleucyl-L-valyl)-N-((S)-1-amino-1-oxopropan-2-yl)pyrrolidine-2-carboxamide
InChi Key
ZUJBBVJXXYRPFS-DYKIIFRCSA-N
InChi Code
InChI=1S/C25H47N9O5/c1-6-14(4)19(33-21(36)16(26)9-7-11-30-25(28)29)23(38)32-18(13(2)3)24(39)34-12-8-10-17(34)22(37)31-15(5)20(27)35/h13-19H,6-12,26H2,1-5H3,(H2,27,35)(H,31,37)(H,32,38)(H,33,36)(H4,28,29,30)/t14-,15-,16-,17-,18-,19-/m0/s1
SMILES Code
C[C@@H](C(N)=O)NC([C@H]1N(C([C@H](C(C)C)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)N)=O)=O)=O)CCC1)=O
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
  This agent promotes monocyte and macrophage recruitment to, and accelerates healing in damaged and infected tissue; it suppresses inflammation through the regulation of the expression of multiple cytokines. This agent may prevent or decrease chemo- or radiotherapy-induced mucositis as well as other types of infection. p62, an intracellular adaptor protein that functions downstream of certain signaling receptors, plays a key role in the activation of the innate immune system    

Preparing Stock Solutions

The following data is based on the product molecular weight 553.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
 1: Kudrimoti M, Curtis A, Azawi S, Worden F, Katz S, Adkins D, Bonomi M, Elder J, Sonis ST, Straube R, Donini O. Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study. J Biotechnol. 2016 Oct 13;239:115-125. doi: 10.1016/j.jbiotec.2016.10.010. [Epub ahead of print] PubMed PMID: 27746305. 2: North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O. A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy. J Biotechnol. 2016 May 20;226:24-34. doi: 10.1016/j.jbiotec.2016.03.032. PubMed PMID: 27015977; PubMed Central PMCID: PMC4867239.